KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Receivables (2020 - 2025)

Esperion Therapeutics' Change in Receivables history spans 6 years, with the latest figure at $21.2 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 72.19% year-over-year to $21.2 million; the TTM value through Dec 2025 reached $60.0 million, up 89.74%, while the annual FY2025 figure was $60.0 million, 89.74% up from the prior year.
  • Change in Receivables reached $21.2 million in Q4 2025 per ESPR's latest filing, up from $11.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $26.5 million in Q2 2025 to a low of -$144000.0 in Q3 2021.
  • Average Change in Receivables over 5 years is $6.4 million, with a median of $4.5 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: plummeted 105.01% in 2021, then soared 2631.25% in 2022.
  • A 5-year view of Change in Receivables shows it stood at $1.2 million in 2021, then skyrocketed by 83.01% to $2.2 million in 2022, then surged by 162.1% to $5.9 million in 2023, then surged by 109.81% to $12.3 million in 2024, then soared by 72.19% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Change in Receivables are $21.2 million (Q4 2025), $11.2 million (Q3 2025), and $26.5 million (Q2 2025).